Market News & Trends
Piramal Healthcare to Buy US Drug Data Firm for $635 Million
Piramal Healthcare Limited recently announced it has agreed to acquire Decision Resources Group for a consideration of approximately $635 million. Decision Resources Group provides high-quality,…
Ra Pharma Closes $8.6-Million Second Tranche of $27 Million Series A
Ra Pharmaceuticals recently announced it is pursuing hereditary angioedema (HAE) as a lead program, leveraging the company's proprietary Cyclomimetic drug discovery and development platform. HAE…
5/16/2012
Mucosis Announces Positive Data for Mimopath Platform Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal vaccines are safe and well…
Cornerstone to Acquire EKR Therapeutics for $150 Million
Cornerstone Therapeutics Inc. and EKR Therapeutics, Inc. recently announced they have entered into a definitive merger agreement whereby Cornerstone Therapeutics will acquire EKR Therapeutics. The…
INTAC Technology Combats Misuse of Extended-Release Drugs
During this year's Annual Scientific Meeting of the American Pain Society (May 16-19, 2012, Honolulu, HI), Grunenthal presented results from clinical studies utilizing a product…
Mucosis Announces Positive Data for Mimopath Platform
Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal vaccines are safe and well tolerated as well as able to produce…
Novozymes Now Supplying Hyasis, a Novel Pharmaceutical-Grade HA
Novozymes Biopharma, part of Novozymes A/S, recently announced the first shipment of the company's Bacillus-derived hyaluronic acid, Hyasis, from its newly inaugurated manufacturing facility in…
Nuevolution Receives Milestone Payment From Boehringer Ingelheim
Nuevolution A/S recently announced that it has received a milestone payment derived from its collaboration with Boehringer Ingelheim. The payment was triggered following identification of…
OncoMed Pharmaceuticals Files for $115-Million IPO
OncoMed Pharmaceuticals Inc. recently announced it is seeking $115 million in an initial public stock offering. The Redwood City-based cancer drug developer, one of the…
5/9/2012
Caisson Biotech Enters Potential $100 Million Agreement Caisson Biotech, L.L.C. recently announced it has entered into a development and license agreement with Novo Nordisk A/S.…
Caisson Biotech Enters Potential $100 Million Agreement
Caisson Biotech, L.L.C. recently announced it has entered into a development and license agreement with Novo Nordisk A/S. The agreement gives Novo Nordisk the exclusive…
Celsion & Focused Ultrasound to Explore ThermoDox Combined With Focused Ultrasound
Celsion Corporation and the Focused Ultrasound Foundation recently announced their support for preclinical studies designed to explore the use of ThermoDox, Celsion's Phase III, proprietary,…
Midatech & MonoSol Rx Announce Positive Results for Transbuccal Oral Insulin Film
Midatech Ltd. and MonoSol Rx LLC recently announced positive bioavailability and pharmacokinetic results from a first-in-human Phase I clinical study of their Midaform Insulin PharmFilm…
Novozymes' rAlbumin Supports Faster Time-to-Market for Neomend Adhesion Barrier Sealant
Novozymes Biopharma recently announced that its recombinant human albumin (rAlbumin), Albucult, is being used by Neomend in the company's Progel Adhesion Barrier Sealant product, which…
Prosonix Demonstrates Improved Delivery & Co-Localization of Respiratory Medicines
Prosonix recently announced the publication of a new review paper describing how its novel particle-engineering-led approach to respiratory medicines is enabling the development of "smart"…
Royalty Pharma Buys an Interest in Fumaderm for $761 Million
Royalty Pharma recently announced it had acquired an interest in the earn-out payable to the former shareholders of Fumapharm AG for $761 million in cash.…
5/1/2012
3M DDS to Enhance Manufacturing Capabilities 3M Drug Delivery Systems recently announced the expansion of the pressurized metered dose inhaler (pMDI) fill line at its facility in…
AAIPharma Services Opens New Technology Center, Will Add Jobs
AAIPharma Services Corp. officially opened a 40,000-sq-ft, state-of-the-art Technology Center on its Wilmington, NC, headquarters campus as part of a $15-million capital expansion program. The…
Harlan & Ipsen Enter Agreement to Enhance Early Stage Development Services
Harlan Laboratories Contract Research Services (CRS) and Ipsen, a global specialty-driven pharmaceutical company, recently announced they have strengthened their collaboration with a new business agreement.…
OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery
OncoSec Medical Inc., which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, recently announced positive interim analysis of data…
